A mocking finding: Portal cavernoma mimicking neoplastic mass: first sign of myeloproliferative disorder in a patient with Janus kinase2 V617F mutation

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 2, 2009, Pages 233-236

  Galati, Giovanni ^a   Gentilucci, Umberto Vespasiani ^a   Sansoni, Llaria ^a   Spataro, Sandro ^a   Di Matteo, Francesco M ^a   Zardi, Enrico M ^a   Grasso, Rosario F ^a   Avvisati, Giuseppe ^b   Afeltra, Antonella ^a   Picardi, Antonio ^a,b  

^a Gl Endoscopy Unit   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Extrahepatic portal vein thrombosis; Myeloproliferative disorders; Portal cavernoma; Pseudo cholangiocarcinoma sign; V617F janus kinase2 mutation

Indexed keywords

ANTIEMETIC AGENT; JANUS KINASE 2; PROTON PUMP INHIBITOR; JAK2 PROTEIN, HUMAN;

ABDOMINAL TENDERNESS; ADULT; ANAMNESIS; ARTICLE; ASCITES; CASE REPORT; CAVERNOUS HEMANGIOMA; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGOGASTRODUODENOSCOPY; ESOPHAGUS VARICES; HUMAN; HYPERBILIRUBINEMIA; HYPERGAMMAGLOBULINEMIA; LABORATORY TEST; LIVER TUMOR; MALE; MESENTERIC VEIN THROMBOSIS; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; POINT MUTATION; PORTAL HYPERTENSION; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SPLENOMEGALY; STOMACH VARICES; VEIN LIGATION; DIFFERENTIAL DIAGNOSIS; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PATHOLOGY; PORTAL VEIN; VENOUS THROMBOSIS;

DIAGNOSIS, DIFFERENTIAL; HUMANS; JANUS KINASE 2; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PORTAL VEIN; VENOUS THROMBOSIS;

EID: 59149100440     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283207b5a     Document Type: Article

References (17)

1. Bayraktar Y, Balkanci F, Ozenc A, Arslan S, Koseoglu T, Ozdemir A, et al. The 'pseudo-cholangiocarcinoma sign' in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels. Am J Gastroenterol 1995; 90:2015-2019.
2. Bayraktar Y, Balkanci F, Kayhan B, Ozenc A, Arslan S, Telatar H. Bile duct varices or 'pseudo-cholangiocarcinoma sign' in portal hypertension due to cavernous transformation of the portal vein. Am J Gastroenterol 1992; 87:1801-1806.
3. Baxter FJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054-1061.
4. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91:169-175.
5. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132:244-245.
6. Idezuki Y. General rules for recording endoscopic findings of esophagogastric varices (1991). Japanese Society for Portal Hypertension. World J Surg 1995; 19:420-422.
7. Hinshelwood S, Bench AJ, Green AR. Pathogenesis of polycythaemia vera. Blood Rev 1997; 11:224-232.
8. De Stefano V, Teofili L, Leone G, Michiels JJ. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Hemost 1997; 23:411-418.
9. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
10. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553-560.
11. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528-1534.
12. Kairaluoma Ml, Karkola P, Heikkinen D, Huttunen R, Mokka RE, Larmi TK. Mesenteric infarction. Am J Surg 1977; 133:188-193.
13. Patch D, Sabin CA, Goulis J, Gerunda G, Greenslade L, Merkel C, et al. A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology 2002; 123:1013-1019.
14. Lo GH, Chen WC, Chen MH, Hsu PI, Lin CK, Tsai WL, et al. Banding ligation versus nadolol and isosorbide mononitrate for the prevention of esophageal variceal rebleeding. Gastroenterology 2002; 123: 728-734.
15. Villanueva C, Mihana J, Ortiz J, Gallego A, Soriano G, Torras X, et al. Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding. N Engl J Med 2001; 345:647-655.
16. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. QJM 1979; 48:627-639.
17. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al.; Members of the APASL Working Party on Portal Hypertension. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26: 512-519.